Barclays PLC began coverage on shares of Vitamin Shoppe Inc. (NYSE:VSI) in a report released on Thursday morning. The brokerage issued an equal weight rating and a $29.00 price objective on the stock.
Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Vitamin Shoppe from a buy rating to a hold rating in a research report on Wednesday, August 3rd. Jefferies Group reissued a hold rating on shares of Vitamin Shoppe in a research report on Thursday, August 4th. Finally, Wedbush reissued an outperform rating and set a $39.00 price target on shares of Vitamin Shoppe in a research report on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $32.27.
Shares of Vitamin Shoppe (NYSE:VSI) opened at 26.70 on Thursday. Vitamin Shoppe has a 12-month low of $26.02 and a 12-month high of $34.41. The stock has a 50 day moving average price of $27.11 and a 200 day moving average price of $29.26. The firm has a market capitalization of $629.69 million, a P/E ratio of 15.64 and a beta of 0.67.
Vitamin Shoppe (NYSE:VSI) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.59 by $0.04. The company had revenue of $332.70 million for the quarter, compared to analyst estimates of $331.58 million. Vitamin Shoppe had a return on equity of 11.53% and a net margin of 3.56%. The business’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $0.57 earnings per share. Equities analysts anticipate that Vitamin Shoppe will post $2.17 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its stake in shares of Vitamin Shoppe by 22.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,047,529 shares of the company’s stock worth $62,593,000 after buying an additional 374,360 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in shares of Vitamin Shoppe by 20.3% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 1,695,043 shares of the company’s stock worth $51,817,000 after buying an additional 286,515 shares during the period. Norges Bank purchased a new stake in shares of Vitamin Shoppe during the fourth quarter worth $7,955,000. Schroder Investment Management Group purchased a new stake in shares of Vitamin Shoppe during the second quarter worth $4,891,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Vitamin Shoppe by 22.8% in the second quarter. JPMorgan Chase & Co. now owns 594,449 shares of the company’s stock worth $18,172,000 after buying an additional 110,395 shares during the period.
About Vitamin Shoppe
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, which includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats; direct, which sells its products directly to consumers through the Internet, primarily at www.vitaminshoppe.com, and manufacturing, which provides custom manufacturing and private labeling of vitamin, mineral and supplement (VMS) products.
Receive News & Ratings for Vitamin Shoppe Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc. and related companies with MarketBeat.com's FREE daily email newsletter.